Table 1. Characteristics of testicular cancer survivors who developed stomach cancer and matched controlsa.
| Cases (N=92) | Controls (N=180) | |
|---|---|---|
| N (%) | N (%) | |
|
Registryb | ||
| The Netherlandsc | 22 (23.9) | 50 (27.8) |
| Sweden | 20 (21.7) | 40 (22.2) |
| Denmark | 20 (21.7) | 30 (16.7) |
| Norway | 18 (19.6) | 36 (20.0) |
| Finland | 7 (7.6) | 14 (7.8) |
| Ontario | 5 (5.4) | 10 (5.6) |
|
Year of testicular cancer diagnosis | ||
| 1959–1969 | 28 (30.4) | 51 (28.3) |
| 1970–1979 | 44 (47.8) | 87 (48.3) |
| 1980–1987 | 20 (21.7) | 42 (23.3) |
|
Age at testicular cancer diagnosis (years) | ||
| 18–29 | 17 (18.5) | 36 (20.0) |
| 30–39 | 35 (38.0) | 70 (38.9) |
| 40–49 | 23 (25.0) | 42 (23.3) |
| 50–59 | 12 (13.0) | 23 (12.8) |
| 60–71 | 5 (5.4) | 9 (5.0) |
|
Testicular cancer histology | ||
| Seminoma | 60 (65.2) | 121 (67.2) |
| Non-seminoma | 32 (34.8) | 58 (32.2) |
| Otherd | 0 (0) | 1 (0.6) |
|
Testicular cancer stage | ||
| I/IIe | 88 (95.7) | 172 (95.6) |
| III/IV | 4 (4.3) | 6 (3.3) |
| Unknown | 0 (0) | 2 (1.1) |
|
Testicular cancer laterality | ||
| Left | 37 (40.2) | 78 (43.3) |
| Right | 54 (58.7) | 100 (55.6) |
| Synchronous | 1 (1.1) | 1 (0.6) |
| Unknown | 0 (0) | 1 (0.6) |
|
Testicular cancer treatment following orchiectomy | ||
| Radiotherapy only | 74 (80.4) | 141 (78.3) |
| Radiotherapy and chemotherapy | 13 (14.1) | 10 (5.6) |
| Chemotherapy only | 1 (1.1) | 13 (7.2) |
| No chemotherapy, no radiotherapy | 3 (3.3) | 16 (8.9) |
| Unknown | 1 (1.1) | 0 (0) |
|
Radiation treatment fields (for patients who received radiotherapy) | ||
| Dog-leg/inverted Y/spade only | 28 (32.2) | 70 (46.4) |
| Dog-leg/inverted Y/spade plus pelvis only | 1 (1.1) | 3 (2.0) |
| Dog-leg/inverted Y/spade plus supradiaphragmatic fields (mediastinum, neck/supraclavicular, other chest) only | 10 (11.5) | 7 (4.6) |
| Para-aortic plus pelvis only | 22 (25.3) | 30 (19.9) |
| Others | 26 (29.9) | 41 (27.2) |
|
Interval from testicular cancer to stomach cancer (years) | ||
| 7–9 | 9 (9.8) | |
| 10–14 | 26 (28.3) | |
| 15–19 | 23 (25.0) | |
| 20–24 | 23 (25.0) | |
| 25–39 | 11 (12.0) | |
|
Year of stomach cancer diagnosis | ||
| 1975–1984 | 20 (21.7) | |
| 1985–1994 | 39 (42.4) | |
| 1995–2004 | 33 (35.9) | |
|
Age at stomach cancer diagnosis (years) | ||
| 31–49 | 24 (26.1) | |
| 50–59 | 31 (33.7) | |
| 60–80 | 37 (40.2) | |
|
Stomach cancer histology | ||
| Adenocarcinoma | 82 (89.1) | |
| Other/unknownf | 10 (10.9) | |
|
Stomach cancer siteg | ||
| Proximal | 22 (23.9) | |
| Body | 10 (10.9) | |
| Lesser curvature | 12 (13.0) | |
| Greater curvature | 5 (5.4) | |
| Distal | 41 (44.6) | |
| Not otherwise specified | 2 (2.2) | |
Patients were ineligible as cases or controls after the occurrence of a second non-stomach cancer (except metachronous testicular cancer that occurred in 3 cases and 3 controls and non-melanoma skin cancer), because it was logistically not feasible to collect detailed treatment information on multiple cancers.
Cases and controls were selected from a cohort of 22 269 testicular cancer (TC) survivors including 6858 patients from Denmark, 1346 from Finland, 1300 from Iowa, 3440 from Ontario, 4732 from Sweden, 1886 from Norway and 2707 from The Netherlands.
Patients from a previous report (Van den Belt-Dusebout et al, 2009) were included in the current study.
First primary non-germ cell tumour of the testis.
In this group, 12 cases and 12 controls were coded as localised, 3 controls were coded as regional and 1 case and 7 controls were coded as localised/regional.
Includes 5 carcinoma not otherwise specified, 1 neuroendocrine carcinoma, 1 other specified and 3 unknown.
Proximal includes cardia (n=17 cases), stump cancer (4) and gastro-oesophageal junction (1); body includes body (8), fundus/body (1), body/antrum (1); distal includes antrum (25), pylorus (15) and antrum/pylorus (1).